These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 3969034)

  • 1. Vindesine in the treatment of refractory haematological malignant diseases.
    Young GA; Jurd J; Vincent PC
    Med J Aust; 1985 Feb; 142(3):189-90. PubMed ID: 3969034
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Phase II study of vindesine in hematological malignancies].
    Gan To Kagaku Ryoho; 1983 Dec; 10(12):2509-15. PubMed ID: 6580841
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Continuous 5-day vindesine in the treatment of leukemias and lymphomas (author's transl)].
    Maraninchi D; Gastaut JA; Tubiana N; Carcassonne Y
    Bull Cancer; 1981; 68(4):338-42. PubMed ID: 6947833
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Administration of vindesine sulfate for the treatment of malignant hematological tumors].
    Ueda T; Masaoka T; Shibata H; Kubota Y; Saigo K; Kusakabe H; Takubo T; Nakamura H; Yoshitake J; Ishigami S
    Gan To Kagaku Ryoho; 1982 Feb; 9(2):306-15. PubMed ID: 6764103
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination of vindesine and prednisone in malignant lymphoma and acute leukemia.
    Raich PC; Walker BK; Rogers JS; Subramanian VP; Fontana JA; Knost JA; Denning B
    Cancer Treat Rep; 1983 May; 67(5):485-7. PubMed ID: 6573959
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Leukaemias and lymphomas treatment by vindesine. Result of a phase II trial in terms of remission induction (author's transl)].
    Marthé G; Misset JL; de Vassal F; Hayat M; Gouveia J; Machover D; Belpomme D; Schwarzenberg L; Ribaud P; Pico JL; Musset M; Jasmin C; de Luca L
    Nouv Presse Med; 1978 Feb; 7(7):525-8. PubMed ID: 273888
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vindesine in the treatment of refractory hematologic malignancies: a phase II study.
    Mandelli F; Amadori S; Giona F; Antonietta M; Spiriti A; Pastore S; Meloni G; Paolucci G
    Leuk Res; 1982; 6(5):649-52. PubMed ID: 7154707
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vindesine: a new vinca alkaloid.
    Bayssas M; Gouveia J; de Vassal F; Misset JL; Schwarzenberg L; Ribaud P; Musset M; Jasmin C; Hayat M; Mathé G
    Recent Results Cancer Res; 1980; 74():91-7. PubMed ID: 7003662
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased schedule-dependent synergism of vindesine versus vincristine in combination with methotrexate against L1210 leukemia.
    Chello PL; Sirotnak FM
    Cancer Treat Rep; 1981; 65(11-12):1049-53. PubMed ID: 7296551
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Initial clinical studies of vindesine.
    Valdivieso M; Richman S; Burgess AM; Bodey GP; Freireich EJ
    Cancer Treat Rep; 1981; 65(9-10):873-5. PubMed ID: 6268296
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II evaluation of vindesine in mycosis fungoides, extraosseous plasmacytoma and other hematologic malignancies.
    Ferrazzi E; Pappagallo GL; Segati R; Vinante O; Galligioni E; Zagonel V; Salvagno L; Fiorentino MV
    Tumori; 1982 Aug; 68(4):321-4. PubMed ID: 7147357
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sequential combination of methotrexate and vindesine in previously treated children with acute leukemia. A phase I-II study.
    Miller LP; Hancock C; Miller DR; Chello PL; Sirotnak FM; Tan CT
    Am J Clin Oncol; 1984 Oct; 7(5):465-70. PubMed ID: 6594925
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacology, clinical efficacy and adverse effects of vindesine sulfate, a new vinca alkaloid.
    Cersosimo RJ; Bromer R; Licciardello JT; Hong WK
    Pharmacotherapy; 1983; 3(5):259-74. PubMed ID: 6359081
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparative randomized trial of vinca alkaloids in patients with metastatic breast carcinoma.
    Yau JC; Yap YY; Buzdar AU; Hortobagyi GN; Bodey GP; Blumenschein GR
    Cancer; 1985 Jan; 55(2):337-40. PubMed ID: 3880657
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A study of the cross-resistance of vincristine and vindesine in reinduction therapy for acute lymphocytic leukemia in relapse. A report for Children's Cancer Study Group.
    Krivit W; Anderson J; Chilcote R; Pyesmany A; Chard R; Hammond D
    Am J Pediatr Hematol Oncol; 1980; 2(3):217-21. PubMed ID: 7001942
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dyspnea following vinblastine or vindesine administration in patients receiving mitomycin plus vinca alkaloid combination therapy.
    Kris MG; Pablo D; Gralla RJ; Burke MT; Prestifilippo J; Lewin D
    Cancer Treat Rep; 1984; 68(7-8):1029-31. PubMed ID: 6744336
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Broad phase II study of vindesine.
    Valdivieso M; Bedikian AY; Bodey GP; Freireich EJ
    Cancer Treat Rep; 1981; 65(9-10):877-9. PubMed ID: 7273021
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II evaluation of vindesine in the treatment of colorectal and esophageal tumors.
    Bedikian AY; Valdivieso M; Bodey GP; Freireich EJ
    Cancer Chemother Pharmacol; 1979; 2(4):263-6. PubMed ID: 455586
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase-II trial with vindesine for regression induction in patients with leukemias and hematosarcomas.
    Bayssas M; Gouveia J; Ribaud P; Musset M; de Vassal F; Pico JL; de Luca L; Misset JL; Machover D; Belpomme D; Schwarzenberg L; Jasmin C; Hayat M; Mathé G
    Cancer Chemother Pharmacol; 1979; 2(4):247-55. PubMed ID: 287569
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vindesine and prednisone for remission induction in children with acute lymphocytic leukemia.
    Vats TS; Mehta P; Trueworthy RC; Smith SD; Klopovich P
    Cancer; 1981 Jun; 47(12):2789-92. PubMed ID: 6942907
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.